Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus pembrolizumab in advanced or metastatic squamous non-small cell lung cancer
2016-005042-37Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and pembrolizumab in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma, sponsored by Boehringer Ingelheim. Primary endpoint: Objective response. Started Jun 2017; status: completed.
02
Drugs
afatinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2016-005042-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005042-37.